Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.creator | Sampaio, Raimunda Nonata Ribeiro | - |
Autor(es): dc.creator | Silva, Juliana Saboia Fontenele e | - |
Autor(es): dc.creator | Paula, Carmen Dea Ribeiro de | - |
Autor(es): dc.creator | Porto, Cláudia | - |
Autor(es): dc.creator | Motta, Jorgeth de Oliveira Carneiro da | - |
Autor(es): dc.creator | Pereira, Ledice Inacia de Araujo | - |
Autor(es): dc.creator | Martins, Sofia Sales | - |
Autor(es): dc.creator | Barroso, Daniel Holanda | - |
Autor(es): dc.creator | Freire, Gustavo Subtil Magalhães | - |
Autor(es): dc.creator | Gomes, Ciro Martins | - |
Data de aceite: dc.date.accessioned | 2024-10-23T16:14:29Z | - |
Data de disponibilização: dc.date.available | 2024-10-23T16:14:29Z | - |
Data de envio: dc.date.issued | 2020-01-23 | - |
Data de envio: dc.date.issued | 2020-01-23 | - |
Data de envio: dc.date.issued | 2019 | - |
Fonte completa do material: dc.identifier | https://repositorio.unb.br/handle/10482/36245 | - |
Fonte completa do material: dc.identifier | https://doi.org/10.1590/0037-8682-0292-2018 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0002-8223-0058 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/capes/903340 | - |
Descrição: dc.description | INTRODUCTION: The treatment of mucosal leishmaniasis (ML) is difficult due to the toxicity and route of administration of standard drugs. Miltefosine is an oral agent used for leishmaniasis treatment; however, no data exist regarding its use for ML in Brazil. In this study, we aimed to evaluate the efficacy of miltefosine for ML treatment compared to that of pentavalent antimonial in a pilot study. METHODS: We performed a randomized clinical trial with two parallel groups. The tested intervention consisted of miltefosine 1.3-2 mg/kg/day (two capsules) for 28 days or intravenous 20 mg SbV/kg/day of meglumine antimoniate (N-MA) for 30 days. The final endpoint was defined as complete healing of the lesion four years after treatment. We also analyzed an early endpoint at 90 days after treatment. RESULTS: Forty patients were included in this study: each experimental group comprised 20 patients. Applying a multivariate model in an intention-to-treat analysis, we observed that patients treated with miltefosine had a cure probability 2.08 times greater (95% confidence interval [CI] = 1.03-4.18) than those treated with N-MA at 90 days after treatment. At the final endpoint, we observed no differences in cure probability between miltefosine and N-MA (relative risk = 0.66; 95% CI = 0.33-1.32). With respect to adverse reactions, significant differences between groups were related to gastrointestinal effects, which were more frequent in the miltefosine group. CONCLUSIONS: Miltefosine may be an interesting alternative for treating ML because of its oral administration and cure rate after long-term follow-up. | - |
Descrição: dc.description | Faculdade de Medicina (FMD) | - |
Formato: dc.format | application/pdf | - |
Idioma: dc.language | en | - |
Publicador: dc.publisher | Sociedade Brasileira de Medicina Tropical - SBMT | - |
Direitos: dc.rights | Acesso Aberto | - |
Direitos: dc.rights | OPEN ACCESS - https://creativecommons.org/licenses/by/4.0/. (CC BY). | - |
Palavras-chave: dc.subject | Leishmaniose | - |
Palavras-chave: dc.subject | Leishmaniose tegumentar americana | - |
Palavras-chave: dc.subject | Ensaios clínicos | - |
Palavras-chave: dc.subject | Terapêutica | - |
Palavras-chave: dc.subject | Medicamentos | - |
Título: dc.title | A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis | - |
Tipo de arquivo: dc.type | livro digital | - |
Aparece nas coleções: | Repositório Institucional – UNB |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: